BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32880259)

  • 1. HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy.
    Mikasi SG; Ikomey GM; Obasa AE; Cloete R; Jacobs GB
    S Afr Med J; 2020 Aug; 110(9):13071. PubMed ID: 32880259
    [No Abstract]   [Full Text] [Related]  

  • 2. The promise of paediatric dolutegravir.
    Golin R; Samuel JM; Phelps BR; Persaud U; Malati CY; Siberry GK
    J Int AIDS Soc; 2021 Jan; 24(1):e25660. PubMed ID: 33522081
    [No Abstract]   [Full Text] [Related]  

  • 3. Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor.
    Piacentini D; Lanzafame M; Rizzardo S; Chiesi S; Lattuada E; Mehrabi S; Zamboni G; Mazzi R; Tacconelli E; Vento S
    Int J STD AIDS; 2020 Dec; 31(14):1407-1410. PubMed ID: 33081650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.
    Braun DL; Scheier T; Ledermann U; Flepp M; Metzner KJ; Böni J; Günthard HF
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33228206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in the HIV-1 3'-Polypurine Tract Can Confer Dolutegravir Resistance.
    Dekker JG; Klaver B; Berkhout B; Das AT
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0102721. PubMed ID: 34633840
    [No Abstract]   [Full Text] [Related]  

  • 6. Dosing of Dolutegravir in TB/HIV Coinfected Patients on Rifampicin: Twice Is (Always) Better Than Once.
    Cattaneo D; Riva A; Columpsi P; Lapadula G; Filice C; Gervasoni C
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):e17-e20. PubMed ID: 32205722
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
    Viani RM; Ruel T; Alvero C; Fenton T; Acosta EP; Hazra R; Townley E; Palumbo P; Buchanan AM; Vavro C; Singh R; Graham B; Anthony P; George K; Wiznia A;
    J Pediatric Infect Dis Soc; 2020 Apr; 9(2):159-165. PubMed ID: 30951600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple choices for HIV therapy with integrase strand transfer inhibitors.
    Raffi F; Wainberg MA
    Retrovirology; 2012 Dec; 9():110. PubMed ID: 23253887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction analysis of statistically enriched mutations identified in Cameroon recombinant subtype CRF02_AG that can influence the development of Dolutegravir drug resistance mutations.
    Mikasi SG; Isaacs D; Chitongo R; Ikomey GM; Jacobs GB; Cloete R
    BMC Infect Dis; 2021 Apr; 21(1):379. PubMed ID: 33892628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
    Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
    Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.
    Salou M; Butel C; Comlan AS; Konou AA; Tegueni K; Ehlan A; Lack F; Dossim S; Ayouba A; Delaporte E; Dagnra AY; Peeters M
    AIDS; 2020 Apr; 34(5):783-787. PubMed ID: 31895149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-cost urine tenofovir assay to triage dolutegravir resistance testing.
    Martinson T; Nwogu-Attah J; Spinelli M; Gandhi M
    Lancet HIV; 2024 May; 11(5):e282-e283. PubMed ID: 38461845
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.
    Nasreddine R; Florence E; Vandercam B; Moutschen M; Goffard JC; De Munter P; Delforge M; Marinus W; De Wit S;
    AIDS; 2020 Jul; 34(8):1151-1159. PubMed ID: 32287063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Dolutegravir and Sertraline on the Blood Brain Barrier (BBB).
    Ma Q; Schifitto G; Venuto C; Ocque A; Dewhurst S; Morse GD; Aalinkeel R; Schwartz SA; Mahajan SD
    J Neuroimmune Pharmacol; 2020 Mar; 15(1):7-9. PubMed ID: 31939069
    [No Abstract]   [Full Text] [Related]  

  • 15. Is resistance to dolutegravir possible when this drug is used in first-line therapy?
    Mesplède T; Wainberg MA
    Viruses; 2014 Aug; 6(9):3377-85. PubMed ID: 25166745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolutegravir drug-resistance monitoring in Africa.
    Kouamou V; Inzaule S; Manasa J
    Lancet HIV; 2021 Nov; 8(11):e664-e666. PubMed ID: 34735801
    [No Abstract]   [Full Text] [Related]  

  • 17. Compelling evidence for unconditional shift to dolutegravir.
    Steegen K; Hans L
    Lancet HIV; 2022 Aug; 9(8):e523-e524. PubMed ID: 35905750
    [No Abstract]   [Full Text] [Related]  

  • 18. Dolutegravir for children with HIV-associated tuberculosis.
    Meyers T; Krogstad P
    Lancet HIV; 2022 Sep; 9(9):e599-e600. PubMed ID: 35868340
    [No Abstract]   [Full Text] [Related]  

  • 19. Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.
    Fulcher JA; Du Y; Zhang TH; Sun R; Landovitz RJ
    Clin Infect Dis; 2018 Aug; 67(5):791-794. PubMed ID: 29933437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling.
    Liu XI; Momper JD; Rakhmanina NY; Green DJ; Burckart GJ; Cressey TR; Mirochnick M; Best BM; van den Anker JN; Dallmann A
    Clin Pharmacokinet; 2020 Nov; 59(11):1433-1450. PubMed ID: 32451908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.